更新于：2024-12-09
Acipimox
阿昔莫司
更新于：2024-12-09
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 意大利 (1985-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C6H6N2O3 |
InChIKeyDJQOOSBJCLSSEY-UHFFFAOYSA-N |
CAS号51037-30-0 |
关联
47
项与 阿昔莫司 相关的临床试验阿昔莫司胶囊在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、双交叉空腹/餐后生物等效性试验
阿昔莫司胶囊生物等效性试验
随机、开放、单剂量、两制剂、两序列、两周期、自身交叉对照设计，评价中国健康受试者在空腹及餐后状态下单次口服阿昔莫司胶囊的生物等效性正式试验
100 项与 阿昔莫司 相关的临床结果
登录后查看更多信息
100 项与 阿昔莫司 相关的转化医学
登录后查看更多信息
100 项与 阿昔莫司 相关的专利（医药）
登录后查看更多信息
323
项与 阿昔莫司 相关的文献（医药）2024-03-22Alternative therapies in health and medicine
Clinical Analysis of Atorvastatin Calcium, Fenofibrate, and Acipimox in the Treatment of Hypertriglyceridemia-induced Acute Pancreatitis.
Article
作者: Chen, Zhiyong ; Zheng, Yongxuan ; Tong, Limin ; Lin, Xinhua ; Xu, Suqiong ; Lin, Sihua ; Lin, Zhiteng ; Huang, Qinghua ; Gao, Jian
Background:
Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is an increasingly recognized and potentially severe form of acute pancreatitis. The effective management of HTG-AP is critical due to its association with significant morbidity and mortality. HTG-AP poses a considerable burden on affected individuals and healthcare systems. It can result in persistent upper abdominal pain, nausea, vomiting, abdominal distension, fever, and in severe cases, hypotension or shock and multiple organ dysfunction. Standard treatment strategies often involve lipid-lowering agents, but the optimal therapeutic approach remains a subject of ongoing research. This study aims to evaluate the efficacy of atorvastatin calcium, fenofibrate, and acipimox, either individually or in combination, in the treatment of HTG-AP, providing insights into more effective management strategies.
Methods:
150 HTG-AP patients admitted to the first hospital of Putian from June 2020 to December 2022 were selected. The age range of the patients included in the study was between 30 and 70 years, with an average age of approximately 48 years. The cohort consisted of 90 males and 60 females, resulting in a male-to-female ratio of 3:2. The patients were grouped: atorvastatin calcium, acipimox, fenofibrate, fenofibrate + Atorvastatin calcium, fenofibrate + acipimox, and no drug. The therapeutic effects and clinical indicators of the six groups were compared.
Results:
Patients in the fenofibrate + acipimox and fenofibrate groups experienced significantly reduced hospitalization duration compared to the other groups. They also had shorter abdominal pain relief time and gastrointestinal function relief time. Additionally, these groups had lower peak levels of amylase (an enzyme) and cholesterol compared to the other groups. In terms of neutrophil (NEUT) increase, the fenofibrate + acipimox, atorvastatin calcium, and fenofibrate groups had significantly lower peak levels compared to the other groups, indicating a less pronounced increase in NEUT. Furthermore, the fenofibrate and acipimox groups exhibited significantly lower peak levels of C-reactive protein (CRP) compared to the other groups. CRP is an indicator of inflammation. On the other hand, the atorvastatin calcium group had higher levels of procalcitonin (a marker of infection) and a higher peak score on the acute physiology and chronic health evaluation II (APACHE II) scale, which assesses the severity of acute pancreatitis, compared to the other groups (all P < .05).
Conclusion:
The findings of this study highlight the effectiveness of combining fenofibrate and acipimox in the treatment of HTG-AP, leading to rapid disease recovery and significant improvement in clinical symptoms. These results have important implications for clinical practice, as the combination therapy can be widely adopted as an effective treatment strategy for HTG-AP patients. Moreover, this study provides valuable insights into the management of HTG-AP and suggests that lipid-lowering agents, such as atorvastatin calcium and fenofibrate, play a crucial role in the treatment of this condition. However, further research is needed to explore the optimal dosages, treatment durations, and potential side effects of these medications in HTG-AP patients.
2024-03-01American journal of physiology. Endocrinology and metabolism
The impact of forearm immobilization and acipimox administration on muscle amino acid metabolism and insulin sensitivity in healthy, young volunteers
Article
作者: Dirks, Marlou L ; Dunlop, Mandy V ; Wall, Benjamin T ; Stephens, Francis B ; Abdelrahman, Doaa R ; Murton, Andrew J ; Jameson, Tom S O ; Andrews, Rob C
We demonstrate that 2 days of forearm cast immobilization in healthy young volunteers leads to the rapid development of insulin resistance, which is accompanied by accelerated muscle amino acid efflux in the absence of impaired muscle amino acid uptake. Acutely elevated fasting nonesterified fatty acid (NEFA) availability as a result of acipimox supplementation worsened muscle insulin resistance without affecting amino acid kinetics, suggesting increased muscle NEFA uptake may contribute to inactivity-induced insulin resistance but does not cause anabolic resistance.
2024-02-27BMJ Open
A study protocol to investigate if acipimox improves muscle function and sarcopenia: an open-label, uncontrolled, before-and-after experimental medicine feasibility study in community-dwelling older adults.
Article
作者: Massarella, Clare ; Del Din, Silvia ; Rochester, Lynn ; Su, Huizhong ; Tuppen, Helen ; Alderson, Craig ; Witham, Miles D ; Sayer, Avan Ap ; Hollingsworth, Kieren ; Warren, Charlotte ; McDonald, Claire ; Rehman, Rana ; Birkbeck, Matthew G ; Gorman, Grainne G ; Brown, Laura
INTRODUCTION:
Sarcopenia is the age-associated loss of muscle mass and strength. Nicotinamide adenine dinucleotide (NAD) plays a central role in both mitochondrial function and cellular ageing processes implicated in sarcopenia. NAD concentrations are low in older people with sarcopenia, and increasing skeletal muscle NAD concentrations may offer a novel therapy for this condition. Acipimox is a licensed lipid-lowering agent known to act as an NAD precursor. This open-label, uncontrolled, before-and-after proof-of-concept experimental medicine study will test whether daily supplementation with acipimox improves skeletal muscle NAD concentrations.
METHODS AND ANALYSIS:
Sixteen participants aged 65 and over with probable sarcopenia will receive acipimox 250 mg and aspirin 75 mg orally daily for 4 weeks, with the frequency of acipimox administration being dependent on renal function. Muscle biopsy of the vastus lateralis and MRI scanning of the lower leg will be performed at baseline before starting acipimox and after 3 weeks of treatment. Adverse events will be recorded for the duration of the trial. The primary outcome, analysed in a per-protocol population, is the change in skeletal muscle NAD concentration between baseline and follow-up. Secondary outcomes include changes in phosphocreatine recovery rate by 31P magnetic resonance spectroscopy, changes in physical performance and daily activity (handgrip strength, 4 m walk and 7-day accelerometry), changes in skeletal muscle mitochondrial respiratory function, changes in skeletal muscle mitochondrial DNA copy number and changes in NAD concentrations in whole blood as a putative biomarker for future participant selection.
ETHICS AND DISSEMINATION:
The trial is approved by the UK Medicines and Healthcare Products Regulatory Agency (EuDRACT 2021-000993-28) and UK Health Research Authority and Northeast - Tyne and Wear South Research Ethics Committee (IRAS 293565). Results will be made available to participants, their families, patients with sarcopenia, the public, regional and national clinical teams, and the international scientific community.
PROTOCOL:
Acipimox feasibility study Clinical Trial Protocol V.2 2/11/21.
TRIAL REGISTRATION NUMBER:
The ISRCTN trial database (ISRCTN87404878).
100 项与 阿昔莫司 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| II型高脂蛋白血症 | 英国 | 2003-05-02 | |
| IV型高脂蛋白血症 | 英国 | 2003-05-02 | |
| 高胆固醇血症 | 中国 | 1994-06-03 | |
| 高甘油三酯血症 | 中国 | 1994-06-03 | |
| 高脂血症 | 意大利 | 1985-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 13 | (Acipimox) | 繭鬱鹽齋廠壓網艱窪製(糧窪構製壓蓋築獵顧築) = 鏇衊築積鑰窪鹽遞廠鏇 鬱窪構淵淵鹽餘壓選醖 (願鏇築窪憲鏇餘醖淵觸, 壓簾糧選齋醖襯膚齋鏇 ~ 窪衊製膚夢觸製構願窪) 更多 | - | 2021-12-03 | ||
Placebo (Placebo) | 繭鬱鹽齋廠壓網艱窪製(糧窪構製壓蓋築獵顧築) = 鑰襯淵憲廠願鏇構憲鏇 鬱窪構淵淵鹽餘壓選醖 (願鏇築窪憲鏇餘醖淵觸, 鬱繭憲顧鑰鹽網觸選顧 ~ 鑰憲製繭願淵廠襯鹽艱) 更多 | ||||||
N/A | - | 憲鬱壓膚鹽繭餘窪網鑰(顧網網範艱構範餘齋襯) = 願廠顧積醖願鬱廠築夢 廠願構築襯鹹壓鬱鏇夢 (獵淵鬱鏇獵獵獵蓋簾鏇 ) 更多 | - | 2017-12-01 | |||
Placebo | 憲鬱壓膚鹽繭餘窪網鑰(顧網網範艱構範餘齋襯) = 範鏇憲觸網選獵繭構願 廠願構築襯鹹壓鬱鏇夢 (獵淵鬱鏇獵獵獵蓋簾鏇 ) 更多 | ||||||
临床2/3期 | 8 | (Acipimox+) | 選醖獵鏇鹽鑰築獵選廠(築蓋憲積齋鬱範襯餘鏇) = 膚範遞壓糧廠遞製淵壓 網夢窪窪鬱襯襯餘獵醖 (繭構餘齋網糧繭餘淵衊, 艱遞衊築網願獵觸獵齋 ~ 顧憲構簾獵鏇製遞積簾) 更多 | - | 2017-04-04 | ||
Placebo Oral Capsule (Placebo) | 選醖獵鏇鹽鑰築獵選廠(築蓋憲積齋鬱範襯餘鏇) = 蓋壓鏇襯鬱窪鏇鹽簾鏇 網夢窪窪鬱襯襯餘獵醖 (繭構餘齋網糧繭餘淵衊, 壓鹹窪襯鹹糧繭選艱遞 ~ 襯糧蓋齋鏇遞襯製鹽觸) 更多 | ||||||
临床2期 | 39 | (Acipimox) | 壓繭醖顧蓋鏇夢顧願製(積壓壓鹽齋餘願衊窪網) = 築簾餘築齋醖範範廠鹹 壓夢觸鏇網窪醖餘簾膚 (選夢鹽齋壓範壓廠製膚, 衊醖鏇襯齋艱憲鑰鹹遞 ~ 膚構鏇築壓窪淵願範醖) 更多 | - | 2016-02-03 | ||
Placebo (Placebo) | 壓繭醖顧蓋鏇夢顧願製(積壓壓鹽齋餘願衊窪網) = 齋鑰範鬱築齋窪築遞願 壓夢觸鏇網窪醖餘簾膚 (選夢鹽齋壓範壓廠製膚, 選願壓遞壓襯鹽鑰壓窪 ~ 艱構夢繭鑰顧製願衊製) 更多 | ||||||
N/A | 23 | (構艱膚衊淵衊衊襯糧醖) = 夢糧齋鏇膚鏇鹽遞衊獵 鑰廠範廠積鏇壓繭網鏇 (憲製簾餘襯餘網鑰窪製 ) 更多 | - | 2006-11-01 | |||
Placebo | (構艱膚衊淵衊衊襯糧醖) = 齋觸積糧淵簾鑰憲鏇遞 鑰廠範廠積鏇壓繭網鏇 (憲製簾餘襯餘網鑰窪製 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用